UNITED THERAPEUTICS CorpUTHR

United Therapeutics Corp (UTHR) reported robust Q1 2026 results with $781.5M revenue and $274.9M net income, underpinned by a 57% operating margin. The pharma company, known for pulmonary hypertension treatments like Tyvaso and Remodulin, generated $463.3M in operating cash flow and held $1.28B cash despite a $100.8M capex spend. Shares outstanding diluted to 47.2M, boosting diluted EPS to $5.82.

UTHR’s core business revolves around niche therapies for rare diseases, a segment that demands high R&D spend ($138.2M quarterly) and careful inventory management. The recent 22.5% inventory increase to $178.3M contrasts with declining sales in legacy products like Nebulized Tyvaso, which fell $33.3M due to lower US volumes. This tension between stockpiling and demand shifts will test management’s supply-chain mettle.

The company’s SEC filings highlight two diverging trends: Tyvaso DPI revenues rose $16M on volume gains, while Remodulin dropped $11M. This product-level volatility matters because UTHR’s $6.7B asset base is heavily tied to these therapies. Meanwhile, the new Stock Incentive Plan allows global share grants, raising questions about alignment between executive incentives and shareholder returns amid $813M liabilities.

Chart watchers note UTHR has traded in a $220-$260 range since 2024, with volume often spiking on FDA announcements. The current $240 handle sits 12% below its 52-week high, a discount that could widen if inventory levels keep climbing without corresponding revenue growth. For now, the cash pile and buyback capacity (unutilized as of Q1) provide a floor, but dilution risks from the incentive plan could cap upside.

Key unanswered questions centre on whether the Tyvaso DPI growth can offset Remodulin’s decline and how effectively UTHR can monetize its $1.28B cash hoard. The lack of buyback activity despite strong free cash flow ($463M operating minus $100M capex) suggests management may be holding fire for acquisitions or R&D bets instead of returning capital-a choice that will define the next phase of investor sentiment.